208 related articles for article (PubMed ID: 21150468)
1. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer.
Hirschowitz EA; Mullins A; Prajapati D; Baeker T; Kloecker G; Foody T; Damron K; Love C; Yannelli JR
J Thorac Oncol; 2011 Jan; 6(1):169-73. PubMed ID: 21150468
[TBL] [Abstract][Full Text] [Related]
2. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
3. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Sanborn RE; Ross HJ; Aung S; Acheson A; Moudgil T; Puri S; Hilton T; Fisher B; Coffey T; Paustian C; Neuberger M; Walker E; Hu HM; Urba WJ; Fox BA
J Immunother Cancer; 2017 Dec; 5(1):103. PubMed ID: 29258618
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for lung cancer.
Hirschowitz EA; Yannelli JR
Proc Am Thorac Soc; 2009 Apr; 6(2):224-32. PubMed ID: 19349492
[TBL] [Abstract][Full Text] [Related]
7. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
[TBL] [Abstract][Full Text] [Related]
8. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.
Sawabata N; Asamura H; Goya T; Mori M; Nakanishi Y; Eguchi K; Koshiishi Y; Okumura M; Miyaoka E; Fujii Y;
J Thorac Oncol; 2010 Sep; 5(9):1369-75. PubMed ID: 20683209
[TBL] [Abstract][Full Text] [Related]
9. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
[TBL] [Abstract][Full Text] [Related]
10. Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis.
Takahashi H; Shimodaira S; Ogasawara M; Ota S; Kobayashi M; Abe H; Morita Y; Nagai K; Tsujitani S; Okamoto M; Suzuki Y; Nakanishi Y; Yonemitsu Y;
Cancer Immunol Immunother; 2016 Sep; 65(9):1099-111. PubMed ID: 27448677
[TBL] [Abstract][Full Text] [Related]
11. Autologous dendritic cell vaccines for non-small-cell lung cancer.
Hirschowitz EA; Foody T; Kryscio R; Dickson L; Sturgill J; Yannelli J
J Clin Oncol; 2004 Jul; 22(14):2808-15. PubMed ID: 15254048
[TBL] [Abstract][Full Text] [Related]
12. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
13. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
14. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
15. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
16. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
[TBL] [Abstract][Full Text] [Related]
17. Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma.
Chen KY; Chang CH; Yu CJ; Kuo SH; Yang PC
Cancer; 2005 Jun; 103(12):2566-74. PubMed ID: 15852359
[TBL] [Abstract][Full Text] [Related]
18. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
Yao L; Xu S; Xu J; Yang C; Wang J; Sun D
Radiat Oncol; 2015 Jan; 10():10. PubMed ID: 25572571
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for lung cancer.
Bradbury PA; Shepherd FA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S164-70. PubMed ID: 18520304
[TBL] [Abstract][Full Text] [Related]
20. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
